NCCN Guidelines® Insights - Non-Small Cell Lung Cancer, Version 1.2020
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy.
Category
  • Lung Cancers
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Biomarker Testing in Non-Small Cell Lung Cancer
New targeted therapy and immunotherapy regimens are frequently approved and added to the NCCN Guidelines® Non-Small Cell Lung Cancer. Newer testing methods are being developed for patients who are not medically fit for invasive testing. Oncologists should be familiar with the current biomarker testing recommendations to improve outcomes for their patients with metastatic NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Smoking Cessation in Patients with Cancer
Providing care for patients with cancer who smoke poses unique challenges for oncology teams already managing a complex disease, and standardized guidance on effective smoking cessation interventions for patients with cancer is needed. NCCN recommends evidence-based approaches to pharmacotherapy and behavior therapy in order to help primary oncology teams to provide cessation support tailored to their patients’ needs.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Radiation Techniques in the Treatment of Lung Cancer
Multidisciplinary evaluations of patients with non-small cell lung cancer (NSCLC) should include radiation oncologists, because radiation therapy (RT) has a potential role in all stages of NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Managing Cancer Pain in the U.S. Opioid Crisis
To ensure safe access to opioid pain medications for patients with cancer, all members of the healthcare team need to understand the benefits of opioids, how to navigate the federal and state programs regulating opioid use, and how to develop strategies to prevent opioid misuse.
Category
  • Pain
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Neuroendocrine Tumors
Clinicians need to stay current on the knowledge of benefits and risks, including the potential for lifetime radiation toxicity, of the multiple acceptable treatment strategies and apply high-level clinical evidence and expert advice to individualize the treatment and maximize outcomes.
Category
  • Neuroendocrine Tumors
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Immunotherapies in Non-Small Cell Lung Cancer
Immunotherapy recommendations for patients with thoracic cancers are rapidly changing, and health care providers are challenged to remain aware of the most current recommendations in the NCCN Guidelines® to improve outcomes for their patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: New Treatments for Metastatic Lung Cancer
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2020
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN.
Category
  • Myeloid Growth Factors
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer
For each of the emerging therapies described (bevacizumab, PARP inhibitors, and HIPEC), the treatment settings, patient selection criteria, and other therapies used in conjunction have varied widely across clinical trials. This has led to much discussion and likely confusion regarding the exact clinical contexts in which these new options should be considered.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation

Pages